Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2019

View Archived Issues

Discovery of novel HCV inhibitor L-0909

GlaxoSmithKline presents the discovery of GSK-778

Epigenetic inactivation of CELF2 associated with shorter overall survival in breast cancer

Phase II results support further study of AAV2-REP1 gene therapy in patients with choroideremia

Novel type of galactosemia caused by GALM gene mutations revealed

Study partially rehabilitates telomerase in cancer

Rock-paper-synthetic biology

Genentech describes lead small-molecule IRAK-4 inhibitors

Asthma symptoms have distinct origins, common target

PRC2 inhibitors patented by Shanghai Institute of Materia Medica, Suzhou Suplead Life Sciences

Bristol-Myers Squibb discovers STING agonists

FDA approves Ofev for interstitial lung disease associated with scleroderma

Phase I results of inhaled 5-azacytidine for the treatment of advanced non-small cell lung cancer

Enanta Pharmaceuticals discloses new farnesoid X receptor agonists

New PD-1/PD-L1 interaction inhibitors described by Gilead Sciences

AstraZeneca presents arginase-1 and arginase-2 inhibitors

Boehringer Ingelheim, Hydra Biosciences patent TRPC6 antagonists

Vicore completes phase I study of angiotensin II type 2 receptor agonist C-21

AstraZeneca reports phase III data on Imfinzi in previously untreated extensive-stage SCLC

Bristol-Myers Squibb designs RORgammaT inverse agonists showing biologic-like efficacy

Theravance reports first-in-human data on TD-8236 for inflammatory lung disease

Acadia's phase III study of pimavanserin in dementia-related psychosis meets primary endpoint

Passage Bio licenses gene therapy program for CMT2A from Penn

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...